Pulmonary Tuberculoses Clinical Trial
Official title:
Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.
NCT number | NCT05097638 |
Other study ID # | 5884 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 20, 2018 |
Est. completion date | February 4, 2020 |
Verified date | October 2021 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Some of pulmonary tuberculous patients who completed their medication course experience lung function impairment
Status | Completed |
Enrollment | 210 |
Est. completion date | February 4, 2020 |
Est. primary completion date | November 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patient completed an outpatient course of standard first line anti-tuberculosis therapy and declared as cured Exclusion Criteria: - Smoker (to avoid spirometry biases). - Extrapulmonary tuberculosis cases - Multidrug resistant tuberculosis - known contraindications to spirometry testing - Individuals with chest wall deformities or neuromuscular diseases - Patients who failed to achieve acceptability and reproducibility criteria of the spirometry test - Defaulter cases or irregular treatment, - known coexisting chronic lung disease as history of asthma or interstitial lung diseases - A history of illicit drug use - Patients with comorbidities: renal and hepatic insufficiency, heart diseases and metabolic disorders. |
Country | Name | City | State |
---|---|---|---|
Egypt | Chest Department-faculty of medicine-Assuit university | Assuit |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post tuberculosis lung functional impairment | spirometry abnormality either: restrictive, obstructive, or mixed | 6 months | |
Primary | post tuberculosis persistent clinical symptoms | either cough , sputum , breathlessness, hemoptysis | 6 months | |
Primary | Grading of obstruction function: | grading according to GOLD : mild , moderate , severe , very severe | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04085133 -
Prevalence and Burden of Bronchiectasis in Tuberculous Patients
|
||
Recruiting |
NCT05017324 -
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
|
N/A | |
Completed |
NCT04207112 -
Economic Evaluation of New MDR TB Regimens
|
Phase 2/Phase 3 | |
Completed |
NCT04044001 -
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03159975 -
Safety and Immunogenicity Study of GX-70 in TB Patient
|
Phase 1 | |
Completed |
NCT02984579 -
Line Probe Assay Evaluation Study
|
N/A | |
Completed |
NCT05568368 -
Time-to-Detection in Culture of Mycobacterium Tuberculosis
|
||
Recruiting |
NCT04930978 -
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
|
||
Not yet recruiting |
NCT05477966 -
A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
|
||
Active, not recruiting |
NCT05045391 -
Pulmonary Aspergillosis in Tuberculosis Patients
|
||
Completed |
NCT02754765 -
Evaluating Newly Approved Drugs for Multidrug-resistant TB
|
Phase 3 | |
Active, not recruiting |
NCT03896685 -
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
|
Phase 3 |